Netherlands (NL)

Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial (2019) Stone J, Bao M, Han J, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Conference contribution Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial (2019) Stone J, Han J, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Conference contribution Relation of MRI-detected Structural Damage in the Patellofemoral Joint to Pain and Performance Based Function: The MOST Study (2019) Maxwell J, Neogi T, Crossley K, Macri E, White D, Guermazi A, Roemer F, et al. Conference contribution Serum Calprotectin Is a Prognostic Marker for Drug-Free Remission in RA (2019) De Moel E, Rech J, Mahler M, Roth J, Schouffoer A, Ronday K, Huizinga T, et al. Conference contribution ABSORB bioresorbable scaffold versus Xience metallic stent in acute coronary syndromes with treated with percutaneous coronary intervention. A subanalysis of the COMPARE-ABSORB trial (2019) Van Geuns RJ, Smits PC, Chang CC, Wlodarczyk A, Chevalier B, West N, Gori T, et al. Conference contribution Local topology preservation for vascular centerline matching using a hybrid mixture model (2019) Bayer S, Zhai Z, Strumia M, Tong X, Gao Y, Staring M, Stoel B, et al. Conference contribution, Conference Contribution LUTATHERA (R) in first line therapy of G2 and G3 GEP-NETs (the NETTER-2 study) (2019) Ferone D, Pavel ME, Kunz P, De Herder W, Santoro P, Wegener A, Broberg P, et al. Conference contribution Facilitated Data Relay and Effects on Treatment of Severe Aortic Stenosis in Europe (2019) Steeds RP, Lutz M, Thambyrajah J, Serra A, Schulz E, Maly J, Aiello M, et al. Journal article The impact of chloride secretion on the progression of polycystic kidney disease (2019) Kraus A, Faria D, Schley G, Schödel J, Grampp S, Peters DJ, Schreiber R, et al. Conference contribution Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) (+) ribociclib (RIB) (2019) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Conference contribution